Literature DB >> 23547463

[Three-year efficacy and side effect of adefovir dipivoxil for the treatment of the old patients with chronic hepatitis B virus infection].

Meng-Fei Zhu1, Jian-Cheng Qian, Lu Lu, Feng-Le Yan, Jun-Ping Shi, Guo-Qiang Lou.   

Abstract

OBJECTIVE: To investigate 3-year antiviral efficacy and side effect of adefovir dipivoxil (ADV) on the old patients with hepatitis B chronic infection.
METHODS: 31 HBeAg-negative chronic hepatitis B virus infected old patients (include 8 patients with chronic hepatitis B and 23 patients with liver cirrhosis) with serum HBV DNA levels > 1000 copies/ml, and ALT > 2 times the upper limit of normal, without company with other liver diseases, cancer, renal dysfunction, and autoimmune disease. All the patients were treated with ADV orally (10 mg once daily) for 36 months. HBV DNA and biochemical and blood routine indexes were checked after treated. RESULT: Serum total bilirubin, direct bilirubin, alamine aminotransferase, aspartate aminotransferase and load of HBV DNA decrease significantly after therapy (P < 0. 001). Other biochemical indexs and blood routine are no significant changes (P > 0.05).
CONCLUSION: The way to treat with ADV is safe and effective for old patients with chronic hepatitis B virus infection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23547463

Source DB:  PubMed          Journal:  Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi        ISSN: 1003-9279


  2 in total

1.  Association between adefovir dipivoxil treatment and the risk of renal insufficiency in patients with chronic hepatitis B: A meta-analysis.

Authors:  Qiao Yang; Y U Shi; Ying Yang; Guohua Lou; Fangfang Lv
Journal:  Biomed Rep       Date:  2015-01-07

2.  Relationship between nephrotoxicity and long-term adefovir dipivoxil therapy for chronic hepatitis B: A meta-analysis.

Authors:  Qing Luo; Yong Deng; Feifei Cheng; Juan Kang; Shan Zhong; Dazhi Zhang; Weiqiong Zeng
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.